Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q3 2017 · 10-Q
Revenue—
Net Income$1.23M$1.23M−71.1% vs Q3 2016 EPS Diluted-$0.87-$0.87N/M vs Q3 2016 Operating Income$1,310,420−70.9% Operating Cash Flowderived-$1,225,932N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,227,196N/M ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end